On April 24, 2024 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois (Press release, Precigen, APR 24, 2024, View Source [SID1234642301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title

Abstract #

Presentation Details

PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides
the first treatment that leads to complete and durable responses in
recurrent respiratory papillomatosis patients

LBA6015

Session Title:
Rapid Oral Abstract Session –
Head and Neck Cancer

Session Date and Time:
June 3, 2024
8:00 AM – 9:30 AM CT

Event details are available on Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.